25 May,2021 02:50 PM IST | Mumbai | PTI
Maharashtra Health Minister Rajesh Tope
Maharashtra Health Minister Rajesh Tope on Tuesday said the state would get 60,000 vials of Amphotericin-B, the key drug for the treatment of mucormycosis patients, from June 1 onwards.
There are 2,245 patients of mucormycosis, also known as the black fungus, in Maharashtra, Tope told reporters after attending a review meeting on the mucormycosis and Covid-19 cases in the state.
Tope said the state has floated a global tender for procuring Amphotericin-B vials for the treatment of mucormycosis. "The state would get 60,000 vials of the medicine from June 1 onwards. It will be an additional supply apart from the current allocation of the medicine by the Centre," he said.
Also Read: Maharashtra govt declares Mucormycosis as notifiable disease
ALSO READ
Consensus in MVA over 90 to 95 per cent seats, says Sharad Pawar
Maharashtra Elections 2024: BJP leader Shaina NC takes a dig at Congress
Bandra Terminus stampede: Victims urge railways for improved safety measures
Bandra Terminus stampede: Would reserved seats prevent festival train chaos?
Ex-BJP MP Raosaheb Danve's daughter joins Eknath Shinde-led Shiv Sena
The minister said there are 2,245 patients of black fungus in the state and out of them, 1,007 are already covered under the Mahatma Jyotirao Phule Jan Arogya Yojana (MJPJAY), he said.
"The entire cost of the treatment of mucormycosis patients under the MJPJAY will be free of cost, including the cost of the medicine. The state is also trying to cap the cost of treatment of mucormycosis patients who are admitted in private hospitals," he said.
Tope said the Maharashtra government has issued a GR (government resolution) regarding such treatment and the finance department has allocated Rs 30 crore for the same.
There have been several cases of mucormycosis, a rare but serious fungal infection, among Covid-19 patients in Maharashtra and some other states.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.